Eyenovia Stock Scheduled to Reverse Split on Monday, February 3rd (NASDAQ:EYEN)

Eyenovia, Inc. (NASDAQ:EYEN)’s stock is set to reverse split on the morning of Monday, February 3rd. The 1-80 reverse split was announced on Tuesday, January 28th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, January 31st.

Eyenovia Price Performance

Eyenovia stock opened at $0.04 on Thursday. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.58. The company has a 50-day moving average price of $0.09 and a 200 day moving average price of $0.46. Eyenovia has a 12-month low of $0.04 and a 12-month high of $2.57. The stock has a market cap of $4.15 million, a P/E ratio of -0.05 and a beta of 1.31.

Eyenovia (NASDAQ:EYEN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.02. Eyenovia had a negative net margin of 114,639.41% and a negative return on equity of 1,108.24%. During the same period in the previous year, the business posted ($0.18) earnings per share. Sell-side analysts anticipate that Eyenovia will post -0.5 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on EYEN. William Blair reissued a “market perform” rating on shares of Eyenovia in a research note on Friday, November 15th. HC Wainwright downgraded Eyenovia from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $12.00 to $2.00 in a research report on Monday, November 18th. LADENBURG THALM/SH SH reaffirmed a “neutral” rating on shares of Eyenovia in a research report on Monday, November 18th. Finally, Brookline Capital Management reaffirmed a “hold” rating on shares of Eyenovia in a research note on Friday, November 15th.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Eyenovia in the 2nd quarter valued at $26,000. Financial Management Network Inc. acquired a new position in Eyenovia in the 3rd quarter valued at about $39,000. Nations Financial Group Inc. IA ADV grew its position in Eyenovia by 78.6% in the 3rd quarter. Nations Financial Group Inc. IA ADV now owns 90,900 shares of the company’s stock valued at $47,000 after acquiring an additional 40,000 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in Eyenovia by 36.6% during the third quarter. Geode Capital Management LLC now owns 557,994 shares of the company’s stock worth $288,000 after purchasing an additional 149,471 shares during the period. 25.84% of the stock is currently owned by institutional investors and hedge funds.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.